PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

# **Listing of Claims:**

1. (Currently Amended)

A compound having the formula:

#### where:

n, m and o are, independently, an integer from 1 to about 4;

X is CH<sub>2</sub>, N(R<sup>4</sup>), oxygen or sulfur;

Y is hydrogen, hydroxyl, =0,  $N(R^4)(R^5)$ , or =S;

R<sup>1</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group;

R<sup>2</sup> is an activated ester, a carboxylic acid, an alkyl isothiocyanate, an aromatic isothiocyanate or a leaving group;

R<sup>3</sup> is hydrogen or a protective group;

R<sup>4</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group; and

R<sup>5</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group,

#### wherein:

said protective group is benzyloxycarbonyl or

## said activated ester is

and

# said leaving group is halo, mesylate, tosylate, or trifluorosulfonate.

## 2. (Canceled)

3. (Previously Presented) The compound of claim 1 wherein the carboxylic acid group is:

4. (Previously Presented) The compound of claim 1 wherein the isothiocyanato group is:

$$V_{Z_{7}}$$
 N=C=S or  $V_{Z_{7}}$  or  $V_{Z_{7}}$ 

# 5. (Canceled)

- 6. (Original) The compound of claim 1 wherein the protective group is tert-butoxycarbonyl or benzyloxycarbonyl.
- 7. (Original) The compound of claim 1 wherein n is equal to 1 or 2 and m is equal to 1 or 2.
- 8. (Previously presented) The compound of claim 1 wherein:

n or m or o is 1 or 2;

X is  $N(R^4)$  or oxygen;

Y is hydrogen or =O;

R<sup>1</sup> is hydrogen or methyl;

 $R^2$  is *p*-nitrophenyl ester;

R³ is hydrogen or tert-butyldiphenylsilyl; and

R<sup>4</sup> is methyl, ethyl, propyl or butyl.

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

# 9. (Currently Amended) A compound having the formula:

$$\begin{array}{c|c}
OR^{3} \\
O \\
N \\
R^{1} \\
N \\
OR^{3}
\end{array}$$

$$\begin{array}{c|c}
R^{1} \\
N \\
OR^{3}
\end{array}$$

$$\begin{array}{c|c}
R^{1} \\
N \\
OR^{3}
\end{array}$$

$$\begin{array}{c|c}
R^{3}O \\
R^{1}
\end{array}$$

## where:

n, m and o are, independently, an integer from 1 to about 4;

X is CH<sub>2</sub>, N(R<sup>4</sup>), oxygen or sulfur;

Y is hydrogen, -OH, =O,  $N(R^4)(R^5)$ , or =S;

R<sup>1</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group;

R<sup>2</sup> is an activated ester, a carboxylic acid, an alkyl isothiocyanate, an aromatic isothiocyanate or a leaving group;


R<sup>3</sup> is hydrogen or a protective group;

R<sup>4</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group; and

R<sup>5</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group;

#### wherein

said protective group is benzyloxycarbonyl or



#### said activated ester is

or 
$$\sum_{i=1}^{NO_2} or \sum_{i=1}^{NO_2} or \sum_{i=1}$$

# 10. (Canceled)

11. (Previously Presented) The compound of claim 9 wherein the carboxylic acid group is:

12. (Previously Presented) The compound of claim 9 wherein the isothiocyanato group is:

$$N=C=S$$
 or  $N=C=S$  or  $N=C=S$ 

13. (Canceled)

14. (Original) The compound of claim 9, wherein the protecting group is tert-butoxycarbonyl or benzyloxycarbonyl.

15. (Currently Amended) The compound of claim 9 wherein:

n or m or o is 1 or 2;

X is  $N(R^4)$  or oxygen;

Y is hydrogen or carbonyl;

R<sup>1</sup> is hydrogen or methyl;

 $R^2$  is p-nitrophenyl ester;

R<sup>3</sup> is hydrogen or tert-butyldiphenylsilyl; and

R<sup>4</sup> is methyl, ethyl, propyl or butyl.

16. (Currently Amended) A compound having the formula:

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

where n, m and o are, independently, an integer from 1 to about 4;

X is CH<sub>2</sub>, N(R<sup>4</sup>), oxygen or sulfur;

Y is hydrogen, -OH, =O,  $N(R^4)(R^5)$ , or =S;

R<sup>1</sup> is hydrogen, alkyl having 1 to 4 carbon atoms, or a protective group;

R<sup>2</sup> is an activated ester, a carboxylic acid, or a leaving group;

R<sup>3</sup> is hydrogen or a protective group;

R<sup>4</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group;

R<sup>5</sup> is hydrogen, alkyl having 1 to 5 carbon atoms, or a protective group;

 $Z^1$  is hydrogen,  $N(R^4)(R^5)$ , -OH, =O, or =S; and

 $Z^2$  is hydrogen,  $N(R^4)(R^5)$ , -OH, =O, or =S;

#### wherein

#### said protective group is benzyloxycarbonyl or

#### said activated ester is

and

# said leaving group is halo, mesylate, tosylate, or trifluorosulfonate.

#### 17. (Canceled)

18. (Previously Presented) The compound of claim 16 wherein the carboxylic acid group is:

## Claims 19-21 (Canceled)

22. (Previously presented) The compound of claim 16 wherein:

n or m or o is 1 or 2;

X is  $N(R^4)$  or oxygen;

Y is hydrogen or =O;

R<sup>1</sup> is hydrogen or methyl;

 $R^2$  is p-nitrophenyl ester;

R<sup>3</sup> is hydrogen or tert-butyldiphenylsilyl;

R<sup>4</sup> is methyl, ethyl, propyl or butyl;

 $Z^1$  is -OH; and

Z<sup>2</sup> is hydrogen or -OH.

- 23. (Original) A pharmaceutical composition comprising a compound according to claim 1 in free or in pharmaceutically acceptable salt form and one or more pharmaceutically acceptable carriers or diluents.
- 24. (Original) A pharmaceutical composition comprising a compound according to claim 9 in free or in pharmaceutically acceptable salt form and one or more pharmaceutically acceptable carriers or diluents.

**DOCKET NO.:** DRXI-0144 **Application No.:** 10/634,335

Office Action Dated: March 1, 2006

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

25. (Original) A pharmaceutical composition comprising a compound according to claim 16 in free or in pharmaceutically acceptable salt form and one or more pharmaceutically acceptable carriers or diluents.

26. (Canceled)

27. (Currently Amended) The method of claim 26 40 further comprising detecting said radionuclide in said animal.

Claims 28-30 (Canceled)

31. (Currently Amended) The method of claim 34 43 further comprising the step of detecting said radionuclide in said animal.

Claims 32-36 (Canceled)

37. (Previously Presented) The compound of claim 1 wherein: said protective group is selected from the group comprising benzyloxycarbonyl,

said activated ester is selected from the group comprising

said carboxylic acid is selected from the group comprising

#### PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

said isothiocyanate is selected from the group comprising

$$\searrow N = C = S$$
 ,  $\searrow N = C = S$  and  $\searrow N = C = S$  ; and

said leaving group is selected from the group comprising halo, mesylate, tosylate, and trifluorosulfonate.

38. (Previously Presented) The compound of claim 9 wherein said protective group is selected from the group comprising benzyloxycarbonyl,

said activated ester is selected from the group comprising

said carboxylic acid is selected from the group comprising

said isothiocyanate is selected from the group comprising

$$\lambda = 0$$
 and  $\lambda = 0$  ; and

said leaving group is selected from the group comprising halo, mesylate, tosylate, and trifluorosulfonate.

37 CFR § 1.116

PATENT

39. (Previously Presented) The compound of claim 16 wherein said protective group is selected from the group comprising benzyloxycarbonyl,

said activated ester is selected from the group comprising

said carboxylic acid is selected from the group comprising

said leaving group is selected from the group comprising halo, mesylate, tosylate, and trifluorosulfonate.

- 40. (New) A method of administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 1 complexed with a radionuclide.
- 41. (New) A method of administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 9 complexed with a radionuclide.
- 42. (New) A method of administering to an animal in need thereof a therapeutically effective amount of a compound according to claim 16 complexed with a radionuclide.
- 43. (New) A method comprising administering to an animal in need thereof an amount of a compound according to claim 1 complexed with a radionuclide, wherein said amount is effective to treat a disease selected from the group comprising pituitary tumors,

**DOCKET NO.:** DRXI-0144 **Application No.:** 10/634,335

Office Action Dated: March 1, 2006

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

gastroenteropancreatic tumors, central nervous system tumors, breast tumors, prostatic tumors, ovarian tumors, colonic tumors, small cell lung cancer, paragangliomas, neuroblastomas, pheochromocytomas, medullary thyroid carcinomas, myelomas, metastases, and lymphomas.

- 44. (New) A method comprising administering to an animal in need thereof an amount of a compound according to claim 9 complexed with a radionuclide, wherein said amount is effective to treat a disease selected from the group comprising pituitary tumors, gastroenteropancreatic tumors, central nervous system tumors, breast tumors, prostatic tumors, ovarian tumors, colonic tumors, small cell lung cancer, paragangliomas, neuroblastomas, pheochromocytomas, medullary thyroid carcinomas, myelomas, metastases, and lymphomas.
- 45. (New) A method comprising administering to an animal in need thereof an amount of a compound according to claim 16 complexed with a radionuclide, wherein said amount is effective to treat a disease selected from the group comprising pituitary tumors, gastroenteropancreatic tumors, central nervous system tumors, breast tumors, prostatic tumors, ovarian tumors, colonic tumors, small cell lung cancer, paragangliomas, neuroblastomas, pheochromocytomas, medullary thyroid carcinomas, myelomas, metastases, and lymphomas.